CHANGE IN RATINGS
upgraded at to Outperform at Keefe, Bruyette & Woods. $37 price target. Estimates also raised, as the company again saw improving credit trends in July.
upgraded at UBS. Rating raised to Neutral from Sell. Price target raised to $9.50 from $7.00. 2009 EPS estimates lowered to $1.36 from $1.45.
upgraded at Leerink Swann. Rating raised to Outperform from Market Perform. Raises price target to $15 from $11. Maintains 2009 EPS estimates of $0.57.
Buffalo Wild Wings
rated new Neutral at Goldman. $44 price target. Company has positive long-term potential, but is facing lower restaurant margins in the second half of the year.
upgraded at Oppenheimer. Rating raised to Outperform from Perform. Establishes $19 price target. 2009 EPS estimates lowered to $1.29 from $1.32.
upgraded at Pali to Buy. $210 price target. Estimates also boosted, to reflect higher expected trading revenue and strong banking backlogs.
International Game Technology
upgraded at JP Morgan. Rating raised to Overweight from Neutral. Maintains $23 price target. Maintains 2009 EPS estimates of $0.78.
Pioneer Natural Resources
upgraded at Oppenheimer. Rating raised to Outperform from Perform. Establishes $35 price target. Maintains 2009 EPS estimates of $0.02.
rated new Outperform at Wedbush. $29 price target. Stock is up 30% over the past three months, but the gross margin can still move higher, aided by analog market share gains.
STOCK COMMENTS / EPS CHANGES
target raised at Credit Suisse to $29. Company appears to be past the cyclical bottom. Outperform rating.
estimates, target raised at to Friedman, Billings Ramsey. Shares now seen reaching $23. Estimates also boosted, to match the company's new guidance and the potential from the Varian deal.
estimates boosted at Merrill/BofA through 2011. Company is seeing more demand in the DIY market. Buy rating and $185 price target.
estimates boosted at FBR through 2010. Company should realize cost savings from the Colonial deal. Market Perform rating and $22 price target.
estimates reduced at UBS through 2010. Ultram XL is going generic. Buy rating and $16 price target.
estimates, target raised at Goldman to $27. Estimates were also boosted, to reflect a recovery in the auto market and positive China trends. Neutral rating.
estimates cut at Morgan Stanley through 2011. Latest bond offering will increase interest expense and fundamental visibility remains low. Equal-weight rating.
target raised at Morgan Stanley to $37. Company should be able to expand its gross margin in the coming quarters. Overweight rating.
target cut at Merrill/BofA to $35. Product portfolio is facing increased generic risk. Underperform rating.
2010 estimates cut at Goldman to reflect a slower sales rebound. Buy rating and $23 price target.
estimates increased through 2010 at Friedman, Billings Ramsey. Expect the company to raise guidance later this month. Outperform rating and new $18.50 price target.
estimates, target increased at UBS. Estimates were boosted through 2010. Company seeing higher paint demand and cutting costs. Neutral rating and new $24 price target.
This article was written by a staff member of TheStreet.com.